1. Introduction {#sec1}
===============

Breast cancer is a complex disease with high occurrence. It involves a wide range of pathological entities with diverse clinical courses. Gene and protein expression have been extensively profiled in different subtypes of breast cancer \[[@B1]\]. Growth of human breast cells is closely regulated by hormone receptors. Estrogen receptor (ER), a hormonal transcription factor, plays a critical role in the development of breast cancer. Combined with estrogen, it regulates the expression of multiple genes. Studies have found that ER-positive and ER-negative breast cancers are fundamentally different \[[@B2]\]. The outcome of hormone receptor positive tumors is better than hormone receptor negative tumors \[[@B3]\]. Thus, the identification of ER target genes may reveal critical biomarkers for cancer aggressiveness and is therefore crucial to understanding the global molecular mechanisms of ER in breast cancer. To identify direct target genes of ER, it is necessary to map the ER binding sites across the genome. ChIP-Seq is an effective technology for the genome-wide localization of histone modification and transcription factor binding sites. It enables researchers to fully understand many biological processes and disease states, including transcriptional regulation of ES cells, tissue samples, and cancer cells.

Several previous studies have been dedicated to ER-regulated genes and their function in breast cancer cell line \[[@B4], [@B5]\]. However, most studies lacked the comprehensive and genome-wide view and failed to perform an integrated analysis. In this study, we combined ChIP-Seq and microarray datasets to analyze the ER-regulated genes in the MCF-7 breast cancer cell line. The molecular mechanisms of ER were fully studied, including binding sites, motif, regulated genes, related single nucleotide polymorphisms (SNPs) and functional annotation. The process of this analysis was illustrated in [Figure 1](#fig1){ref-type="fig"}.

2. Materials and Methods {#sec2}
========================

2.1. Datasets {#sec2.1}
-------------

The breast cancer associated ChIP-Seq datasets were extracted from Gene Expression Omnibus (GEO): GSE19013 \[[@B6]\] and GSE14664 \[[@B7]\]. Both datasets can be used to survey genome-wide binding of estrogen receptor (ER) in the MCF-7 breast cancer cell line. Control sample was incorporated for the genomic peak finding of ER. (See [Table 1](#tab1){ref-type="table"} for details.)

2.2. Chip-Seq Analysis {#sec2.2}
----------------------

Bowtie \[[@B8]\] was selected to align sequence tags to human genome. Bowtie is an ultrafast and best short-read aligner. It is suitable for sets of short reads where many reads have at least one good and valid alignment, many reads with relatively high quality, and the number of alignment reported per read is small (closed to 1). ChIP-seq datasets we used were satisfied these criteria. In the analysis, tags were selected using the criterion that alignments had no more than 2 mismatches in the first 35 bases on the high quality end of the read, and the sum of the quality values at all mismatched positions could not exceed 70.

Peak detection algorithm is crucial to the analysis of ChIP-Seq dataset. Currently, several tools are available to identify genome-wide binding sites of transcription factors, such as FindPeaks \[[@B9]\], F-Seq \[[@B10]\], CisGenome \[[@B11]\], MACS \[[@B12]\], SISSRs \[[@B13]\], and QuEST \[[@B14]\]. These different methods have their own advantages and disadvantages, although they act in a similar manner. [Table 2](#tab2){ref-type="table"} showed an overview of the characteristics of these algorithms. ChIP-Seq data has regional biases because of sequencing and mapping biases, chromatin structure, and genome copy number variations \[[@B15]\]. It is believed that more robust ChIP-Seq peak predictions can be obtained by matching control samples \[[@B12]\]. In order to get more stable result, three tools, CisGenome, MACS, and QuEST, were used to identify the binding sites of ER in this study. All the three tools systematically used control samples to guide peak finding and calculate the FDR (False Discovery Rate) value of peaks.

Additionally, MEME program \[[@B16]\] was employed for de novo motif search, keeping default options (minimum width: 6, maximum width: 50, motifs to find: 3, and minimum sites: ≥2). For each site, statistical significance (*P* value) gives the probability of a random string having the same match score or higher. And a criterion of *P*-value \< 0.01 was used here.

2.3. Expression and SNP Analysis {#sec2.3}
--------------------------------

Expression analysis was performed using the same package \[[@B17], [@B18]\]. Differentially expressed genes were selected based on the q-value less than 1%.

Using the table SNP (131) (dbSNP build 131) \[[@B19]\] in UCSC (<http://genome.ucsc.edu/>), we identified SNPs near the ER binding sites. The SNPs with at least one mapping in the regions were selected.

2.4. Functional Annotation {#sec2.4}
--------------------------

Three functional annotation systems, the Gene Ontology (GO) categories \[[@B20]\], canonical KEGG Pathway Maps \[[@B21]\], and commercial software MetaCore-GeneGo Pathway Maps, were used to perform the enrichment analysis for gene function.

Enrichment of GO categories was determined with the Gene Ontology Tree Machine (GOTM) \[[@B22]\], using Hypergeometric test, Multiple test adjustment (BH), and a *P*-value cut-off of 0.01. WebGestalt (WEB-based GEne SeT AnaLysis Toolkit) \[[@B23]\] (<http://bioinfo.vanderbilt.edu/webgestalt/option.php>) was used for enrichment of KEGG Pathway. Hypergeometric test, Multiple test adjustment (BH), and a *P*-value cut-off of 0.01 were also used as criterion. MetaCore-GeneGo is a commercial software which offers gene expression pathway analysis and bioinformatics solutions for systems biology research and development. Hypergeometric intersection was used to estimate *P*-value, the lower *P*-value means higher relevance. *P*-value \< 0.01 and FDR \< 0.05 were used as criterion.

3. Results and Discussion {#sec3}
=========================

3.1. ChIP-Seq Analysis Mapped ER Binding Sites across the Human Genome {#sec3.1}
----------------------------------------------------------------------

Using ChIP-Seq datasets, we identified the global ER binding sites. Sequence tags were firstly aligned to human genome assembly (UCSC, hg19) using Bowtie. Three ChIP-Seq peak calling programs, CisGenome, MACS, and QuEST, were selected to identify the enriched binding peaks. Using a false discovery rate of 0.01, 933 ER binding peaks were revealed by all the three tools in both datasets ([Table 3](#tab3){ref-type="table"}). There were differences among the predicted results using different methods in both two datasets ([Figure 2](#fig2){ref-type="fig"}). The calculated FDR value was not only related to different methods, but also influenced by datasets. The overlapped binding sites seemed to be more robust, with 84.9% having FDR value less than 0.005 in all methods and datasets. These binding sites were used for the following analysis. Firstly, we compared these binding sites with two published studies by Welboren et al. \[[@B7]\] and Hu et al. \[[@B6]\]. Our results showed a substantial overlap with the two studies (77.8 and 78.5%, resp.). Also, 719 binding sites, which were shared by all three studies, were likely to be more reliable. The presence of consensus sequence motifs in the ER binding sites was also examined. De novo motif search using the MEME program \[[@B16]\] identified a refined ERE motif that was markedly similar to the canonical ERE ([Figure 3(a)](#fig3){ref-type="fig"}). Almost all of the ER binding sites contained one or more ERE motif (*P*-value \< 0.01) ([Figure 3(b)](#fig3){ref-type="fig"}). Both published and newly identified binding sites contained at least one ERE motif ([Figure 3(c)](#fig3){ref-type="fig"}).

Furthermore, we examined the location of ER enrichment sites relativer to the nearest-neighbor genes. The result was shown in [Figure 4(a)](#fig4){ref-type="fig"}. Only 8% (72) of the peaks occured within gene promoters (defined here as within 5 kb upstream of 5′ to TSS). Also, 34% (317) of the peaks resided in intragenic sites, including 1% (10) in the 3′UTR, 9% (81) in the 5′UTR, 2% (20) in the exon, and 22% (206) in the intron. The occupancy of enhancer (\>5 kb away 5′ to TSS) was 35% (332). According to [Figure 4(b)](#fig4){ref-type="fig"}, the peaks occurred most frequently between −10 kb to −100 kb, +10 kb to +100 kb, with +10 kb to +100 kb being the highest. A further insight into the peaks within +10 kb to +100 kb showed that peaks were preferably located within the regions spanning from +10 kb to +40 kb ([Figure 4(c)](#fig4){ref-type="fig"}).

3.2. Using Gene Expression Data to Confirm the ER Binding Sites {#sec3.2}
---------------------------------------------------------------

In order to determine the specific gene responses corresponding to ER in MCF-7 cells, we compared the nearest-neighbor genes of ER binding sites to the published studies examining differentially expressed genes between ER+ and ER− breast tumors. We used the 3 studies in [Table 4](#tab4){ref-type="table"} for the gene expression analysis. Differentially expressed genes were selected based on a *q*-value cut-off of less than 1% using a stringent statistical analysis method. We identified 5692 and 6101 up- and downregulated genes. When combined with the nearest-neighbor genes of ER binding sites, 289 up-regulated genes and 198 down-regulated genes were associated with the ER binding sites (see additional file 1, Supplementary Material available online at doi:10.1155/2012/568950). Among these genes, 33 upregulated genes and 11 downregulated genes were also identified by published ChIP-PET analysis \[[@B24]\].

Our analysis found that more binding sites were associated with ER up-regulated genes (60%) compared to down-regulated genes (40%), indicating that ER was more frequently involved in the direct regulation of up-regulated genes. We also examined the location of ER binding sites in up-regulated and down-regulated genes. As shown in [Figure 5](#fig5){ref-type="fig"}, both the up- and down-regulated genes occurred most frequently between −10 kb to −100 kb, +10 kb to +100 kb, which verified the long-range control mode of ER factor.

3.3. SNPs Occurred near the ER Binding Sites {#sec3.3}
--------------------------------------------

Current studies have shown that the breast cancer risks are associated with commonly occurring single nucleotide polymorphisms (SNPs) \[[@B28]--[@B32]\]. The table SNP (131) (dbSNP build 131) in UCSC (<http://genome.ucsc.edu/>) was used to identify SNPs near the ER binding sites. A total of 2694 SNP loci were found and subsequently annotated using dbSNP in NCBI.

Compared with the differently expressed gene set in the vicinity of ER binding sites, 836 SNPs in or near 157 ER-regulated genes were identified (see additional file 2). Most of the SNPs (94.5%) were located in intron and untranslated regions. Only 5.5% were located in the regions of near-gene, coding-synon, missense, and frameshift. These SNPs might have close relationship with breast cancer.

3.4. Functional Annotation of ER Binding Sites {#sec3.4}
----------------------------------------------

To identify the biological processes and pathways altered by ER, we employed three functional annotation systems, the Gene Ontology (GO) categories \[[@B20]\], canonical KEGG Pathway Maps \[[@B21]\], and commercial software MetaCore-GeneGo Pathway Maps, to perform the enrichment analysis for gene function.

To gain an overview of the biological processes in which the nearest-neighbor genes of ER binding sites reside, we firstly performed gene set enrichment analysis using Gene Ontology database. Statistically significant (Hypergeometric test, *P*-value \< 0.01) enriched GO terms were identified using the web tool GOTM (Gene Ontology Tree Machine) \[[@B22]\]. The Gene Ontology Directed Acyclic Graph for the nearest-neighbor genes generated by GOTM was presented in [Figure 6](#fig6){ref-type="fig"}. The terms with red color were significantly enriched. In terms of biological process, negative regulation of biological process and cellular process, cellular component movement, and regulation of localization and locomotion, structure and system development were significantly enriched. Furthermore, whether differently expressed or not, genes were mostly associated with biological regulation and metabolic process in biological process terms, protein binding in molecular function terms, and membrane in cellular component terms (each term included more than 100 genes). Gene functions for all the nearest-neighbor genes were summarized in [Table 5](#tab5){ref-type="table"}.

The KEGG Pathway database (posted on May 23, 2011) was used to identify functional modules regulated by ER. Seventeen significantly enriched pathways (*P*-value \< 0.01) were revealed ([Table 6](#tab6){ref-type="table"}). In these pathways, most genes were also differentially expressed between ER+ and ER− tumors. Pathways in cancer, focal adhesion, axon guidance, regulation of actin cytoskeleton, and MAPK signaling pathway ranked among the most enriched pathways. The top enriched maps, such as focal adhesion pathway and MAPK signaling pathway, were reported to be related with ER in breast cancer. High expression of focal adhesion kinase had been reported to be related to cancer progression of breast. And tumors with high expression of focal adhesion kinase lack ER and PR \[[@B33]\]. It was also reported that hyperactivation of MAPK could repress the ER expression in breast tumors \[[@B34]\]. Pathways in cancer were the top enriched KEGG pathway. The abnormal expression of some genes occurred in several types of cancer \[[@B35]--[@B37]\]. Axon guidance pathway played important roles in cancers. Axon guidance molecules might control the development, migration, and invasion of cancer cells \[[@B38]\]. Regulation of actin cytoskeleton was related to cancer cell migration and invasion \[[@B39]\]. This indicated the crucial role of ER in the development, migration, and invasion of breast cancer.

GeneGo was also used to perform the pathway analysis. Ten pathways were found to be significantly enriched with *P*-value \< 0.01 and FDR \< 0.05 ([Table 7](#tab7){ref-type="table"}). The result showed that ER binding sites were enriched in breast cancer related pathways. Among the top five maps, development_prolactin receptor signaling and development_glucocorticoid receptor signaling had been reported to associate with ER \[[@B40], [@B41]\]. development_ligand-independent activation of ESR1 and ESR2 was another enriched map which might have close relationship with ER. APRIL and BAFF were the members of tumor necrosis factor family which related to a plethora of cellular events from proliferation and differentiation to apoptosis and tumor reduction \[[@B42]\]. IL-22 might play a role in the control of tumor growth and progression in breast \[[@B43]\]. However, the relationship between ER and these two pathways need further experimental study.

4. Conclusions {#sec4}
==============

ER is an important molecular symbol of breast cancer. A full understanding of the molecular mechanisms of ER will be useful for the research in the prediction and treatment of breast cancer. The ChIP-Seq technology is useful to study the interaction of protein and DNA on a genome-wide scale. ChIP-Seq data can effectively analyze the regulatory mechanism of transcription factor in genome-wide scale. In this study, we used ChIP-Seq data to identify the global sites regulated by ER in MCF-7 breast cancer cell line. In order to get more reliable result, three different tools were used to analyze two datasets. And 933 binding sites were identified, and the ERE motif was refined here.

The analysis of the global genomic occupancy of ER-regulated genes revealed that 92% of the total 933 ER-binding sites were located far away from promoters. This suggested that the canonical mode of ER factor function involved long-range control. Previous research had reported that ER-*α* includes looping \[[@B44]\]. Using ChIP-PET, Lin et al. \[[@B24]\] had analyzed the genome-wide ER-*α* chromatin occupancy and revealed abundant nonpromoter sites. Our findings provided further support for this mode of ER factor function.

We compared the ER binding sites found in this study with published differentially expressed genes between ER+ and ER− breast tumors. A set of 487 genes was found significant in discriminating ER status in breast tumors. This indicated that these genes appeared to affect ER response. Only 9% (44) of the genes have been identified by Lin et al. \[[@B24]\], while the remaining need further validations. We found that binding sites were preferentially associated with ER up-regulated genes, indicating that ER was more frequently involved in the regulation of upregulated genes. The location of 487 genes verified the long-range control mode of ER factor.

In this study, we found 2694 single nucleotide polymorphisms loci located in or near the ER binding sites. Among these SNPs, the 157 genes of 836 SNPs were also differentially expressed between ER+ and ER− breast tumors. It indicated that this set of SNPs might have close relationship with ER in breast.

The functional annotation provided a deeper understanding of ER and ER-associated genes. Enrichment analysis of GO gave an overview of gene function. As shown in [Figure 6](#fig6){ref-type="fig"}, significantly enriched terms belonged to three classes, biological regulation, cellular processes, and developmental processes. The result of KEGG enrichment analysis was similar. Five pathways were involved in cellular processes, including focal adhesion, regulation of actin cytoskeleton, oocyte meiosis, endocytosis, and p53 signaling pathway. These pathways were associated with cell communication, movement, growth, and death. Most enriched terms determined by GeneGO were development pathways. It was suggested that ER-regulated genes participated in various development processes. Moreover, KEGG pathway analysis suggested that ER-regulated genes were enriched in some diseases related pathways. Both KEGG and GeneGO pathway analysis revealed that some immune-related pathways were enriched, such as chemokine signaling pathway and immune response_IL-22 signaling pathway. These results indicated that ER-regulated genes related to the development, progression, and metastasis of breast. ER affected every developed stage of breast. However, the regulatory mechanisms of ER in different stages and different pathways still need further studies.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Additional file 1 shows the differentially expressed genes in the vicinity of ER binding sites. Using 3 gene expression studies and a criterion of q-value \<0.01, we identified 5692 and 6101 up- and down-regulated down-regulated genes between ER+ and ER- breast tumors. Among these genes, 289 up-regulated and 198 down-regulated genes located near the ER binding sites. The details of these 489 estrogen response elements were listed here. Additional file 2 shows the SNPs occurred in the ER-regulated genes located near the binding sites. These SNPs were identified by using the table SNP (131) (dbSNP build 131) in UCSC (<http://genome.ucsc.edu/>). Totally, 836 SNPs in or near 157 ER-regulated genes were identified.

###### 

Click here for additional data file.
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![The ChIP-Seq data analyzing pipeline.](CMMM2012-568950.001){#fig1}

![Comparison of QuEST, CisGenome, and MACS predicted result. (a) The FDR value in the dataset of GSE19013. (b) The FDR value in the dataset of GSE14664.](CMMM2012-568950.002){#fig2}

![The genomic binding sites of ER. (a) The consensus motif identified in the ERE binding sites. De novo motif search was performed using the MEME program. (b) The percentage of occurrences of ERE motifs in ER binding sites. (c) Comparison of the occurrences of ERE motifs between published and newly identified binding sites.](CMMM2012-568950.003){#fig3}

![Location analysis of ER binding sites. (a) locations relative to nearest-neighbor genes. (b) Genomic Locations of ER ChIP-Seq peaks. (c) Genomic locations of ER ChIP-Seq peaks within +10\~+100 kb.](CMMM2012-568950.004){#fig4}

![Genomic Locations of differentially expressed genes in the vicinity of ER binding sites.](CMMM2012-568950.005){#fig5}

![Directed Acyclic Graphs (DAGs) of significantly enriched GO (Gene Ontology) categories (*P* \< 0.01).](CMMM2012-568950.006){#fig6}

###### 

The CHIP-Seq datasets.

  Dataset      Platform   Cell line   Sample information
  ------------ ---------- ----------- --------------------
  GSE19013     Illumina   MCF-7       Ethanol treated
  E2-treated                          
  GSE14664     Illumina   MCF-7       ER_minus_ligand
  ER_E2                               

###### 

An overview of the characteristics of different Chip-Seq peak detection algorithm.

  Algorithm   Profile                           Background model    Control sample   Use control to compute FDR
  ----------- --------------------------------- ------------------- ---------------- ----------------------------
  F-Seq       Kernel density estimation (KDE)                       √                 
  FindPeaks   Aggregation of overlapped tags    Monte Carlo                           
  SISSRs      Window scan                       Poisson             √                 
  QuEST       Kernel density estimation (KDE)                       √                √
  MACS        Tags shifted then window scan     dynamic Poisson     √                √
  CisGenome   Strand-specific window scan       Negative binomial   √                √

###### 

Number of ER binding sites identified by three ChIP-Seq peak calling programs (FDR \< 0.01).

             Number of ER binding sites                        
  ---------- ---------------------------- ------ ------ ------ -----
  GSE19013   8137                         5583   5418   2019   933
  GSE14664   6773                         7765   9280   5061   

###### 

Breast cancer gene expression dataset and differently expressed genes number (*q*-value \< 1%).

  ------------------------------------------------------------------------------------------------------------------------------------
  Author                     Journal                   Array type   Sample *N* \   Sample *N* \   Differently expressed genes   
                                                                    ER+            ER−                                          
  -------------------------- ------------------------- ------------ -------------- -------------- ----------------------------- ------
  Graham et al. \[[@B25]\]   Clin Cancer Res           Affy         15             15             709                           333

  Wang et al. \[[@B26]\]     Lancet                    Affy         209            77             2081                          2537

  Lu et al. \[[@B27]\]       Breast Cancer Res Treat   Affy         76             53             5136                          5445

                                                                                                                                

  All                        5692                      6101                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------

###### 

The comparison of top enriched GO categories between different expressed and other nearest-neighbor genes of ER binding sites (number of genes ≥ 100).

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Genes set               Biological process                                                            Molecular function   Cellular component
  ----------------------- ----------------------------------------------------------------------------- -------------------- --------------------
  Differently expressed   Biological regulation, metabolic process,\                                    Protein binding,\    Membrane,\
                          cell communication, organismal process, localization, developmental process   iron binding         nucleus

  Others                  Biological regulation, metabolic process                                      Protein binding      Membrane
  -----------------------------------------------------------------------------------------------------------------------------------------------

###### 

KEGG pathways enriched with the nearest-neighbor genes of ER binding sites (*P*-value \< 0.01).

  KEGG ID    Pathways name                             *P*-value      Number of genes   Number of different expressed genes
  ---------- ----------------------------------------- -------------- ----------------- -------------------------------------
  hsa05200   Pathways in cancer                        2.24*E* − 05   22                16
  hsa04510   Focal adhesion                            0.0002         15                14
  hsa04360   Axon guidance                             0.0009         11                8
  hsa04810   Regulation of actin cytoskeleton          0.0012         14                11
  hsa04010   MAPK signaling pathway                    0.0022         15                12
  hsa04114   Oocyte meiosis                            0.0024         9                 8
  hsa04144   Endocytosis                               0.0024         12                11
  hsa04115   p53 signaling pathway                     0.0024         7                 7
  hsa05216   Thyroid cancer                            0.0024         5                 4
  hsa05218   Melanoma                                  0.0033         7                 3
  hsa04020   Calcium signaling pathway                 0.004          11                4
  hsa04062   Chemokine signaling pathway               0.0064         11                9
  hsa04914   Progesterone-mediated oocyte maturation   0.0085         7                 7
  hsa01100   Metabolic pathways                        0.0086         35                28
  hsa00450   Selenoamino acid metabolism               0.0088         4                 3
  hsa05414   Dilated cardiomyopathy                    0.0096         7                 7
  hsa03440   Homologous recombination                  0.0097         4                 3

###### 

Terms of the enriched GeneGo pathway maps (*P*-value \< 0.01, FDR \< 0.05).

  GeneGo pathway terms                                             *P*-value
  ---------------------------------------------------------------- -----------------
  Apoptosis and survival_APRIL and BAFF signaling                  1.29889*E* − 05
  Development_prolactin receptor signaling                         4.95517*E* − 05
  Development_glucocorticoid receptor signaling                    5.81237*E* − 05
  Development_ligand-independent activation of ESR1 and ESR2       0.000295251
  Immune response_IL-22 signaling pathway                          0.000381484
  Development_EPO-induced Jak-STAT pathway                         0.000531744
  Development_growth hormone signaling via STATs and PLC/IP3       0.000531744
  Cytoskeleton remodeling_keratin filaments                        0.000622315
  Development_GM-CSF signaling                                     0.000660576
  Transcription_transcription regulation of aminoacid metabolism   0.000752764
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